ArticleInternational journal of clinical oncology2026
Treatment sequence after first-line immunotherapy in older adults with advanced NSCLC (NEJ057).
Article in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOptimal management of older patients with advanced non-small cell lung cancer (NSCLC) following progression on immune checkpoint inhibitors (ICIs) remains uncertain, as large-scale evidence guiding second-line therapy in this population is limited. Thus, we performed this study to evaluate transition rates and clinical outcomes of subsequent treatments in older patients with NSCLC after first-line ICI-based therapy.
methodsThis multicenter retrospective cohort study included 1245 patients aged ≥ 75 years with advanced or recurrent epidermal growth factor receptor mutation-negative and anaplastic lymphoma kinase rearrangements-negative NSCLC who received first-line systemic therapy between December 2018 and March 2021 at 58 institutions in Japan. Outcomes included transition rates to second- and third-line therapy, progression-free survival (PFS), overall survival (OS), and objective response rate (ORR).
resultsOf all patients, 354 received ICI plus chemotherapy and 425 received ICI monotherapy. Disease progression occurred in 82% and 77% of patients, respectively. Second-line therapy (most commonly single-agent chemotherapy) was administered to 48% and 31%, respectively. Median PFS with single-agent chemotherapy was 3.7 months in both groups. Median OS was 9.5 and 9.9 months, respectively. ORRs were 11% and 13%, respectively. After progression, 35% and 32% of patients received third-line treatment, which demonstrated limited efficacy. In older patients with advanced NSCLC, transition to second-line therapy after first-line ICI-based treatment was limited. However, the efficacy of single-agent chemotherapy as second-line treatment was comparable to real-world outcomes reported prior to ICIs.
conclusionsThese findings underscore the importance of providing appropriate second-line treatment for older patients. REGISTRY AND REGISTRATION NO. OF THE STUDY/TRIAL: UMIN Clinical Trials Registry (UMIN000046700).
Indexed as
Identifiers
42828636What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.